MilliporeSigma
  • Home
  • Search Results
  • Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Nature reviews. Drug discovery (2013-11-01)
Robert J Harvey, Benjamin K Yee
ABSTRACT

Glycine transporters are endogenous regulators of the dual functions of glycine, which acts as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of neuronal excitation mediated by NMDA (N-methyl-D-aspartate) receptors at glutamatergic synapses. The two major subtypes of glycine transporters, GlyT1 and GlyT2, have been linked to the pathogenesis and/or treatment of central and peripheral nervous system disorders, including schizophrenia and related affective and cognitive disturbances, alcohol dependence, pain, epilepsy, breathing disorders and startle disease (also known as hyperekplexia). This Review examines the rationale for the therapeutic potential of GlyT1 and GlyT2 inhibition, and surveys the latest advances in the biology of glycine reuptake and transport as well as the drug discovery and clinical development of compounds that block glycine transporters.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glycine hydrochloride, ≥99% (HPLC)
Sigma-Aldrich
Glycine, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glycine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Glycine, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Glycine, BioXtra, ≥99% (titration)
Supelco
Glycine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycine, ACS reagent, ≥98.5%
Sigma-Aldrich
Glycine, 99%, FCC
Sigma-Aldrich
Glycine, BioUltra, for molecular biology, ≥99.0% (NT)
Sigma-Aldrich
Glycine, tested according to Ph. Eur.
SAFC
Glycine
USP
Glycine, United States Pharmacopeia (USP) Reference Standard
Glycine, European Pharmacopoeia (EP) Reference Standard